Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2007 Earnings Results

Alnylam Pharmaceuticals Misses on EPS — Stock Down 4.91%

Alnylam Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a decline in stock price by 4.91%. The lack of revenue figures and guidance may raise concerns among investors about the company's near-term performance and strategic direction. The stock's reaction indicates that investors are cautious following these results.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.35	N/A	-58.45%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious approach in their commentary. They emphasized the importance of their ongoing projects but did not provide specific future expectations.

Management did not provide specific guidance for future quarters.

The company is focused on ongoing development and regulatory processes.

Alnylam Pharmaceuticals Misses on EPS — Stock Down 4.91%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Misses on EPS — Stock Down 4.91%

Key numbers

Management commentary